Hayley Binch is Head of Medicinal Chemistry, Basel at Hoffman-La Roche. Prior to her current role, Hayley worked Vertex Pharmaceuticals at both the San Diego and Oxford sites, where she worked on a number of kinases and pain targets as well as Cystic Fibrosis. Hayley completed her her PhD at the University of Bristol with Professor Tim Gallagher, followed by postdoctoral research positions at the University of Hamburg in the area of synthetic and enzymatic methodology for complex carbohydrate assembly and at Kings College London in the area of nucleophilic additions to asymmetric vinylphosphonamidates.

Vicky carried out a PhD and post-doc in total synthesis of macrocyclic natural products at Cambridge University with Prof Ian Paterson and at U Penn with Prof Amos B. Smith, III. Her industrial career initiated at Merck (Terling’s Park) working on neuroscience targets. She then moved to GlaxoSmithKline (Harlow) focussing on anti-infectives and anti-inflammatories. Upon joining Selcia in 2008, she rose from Senior Scientist to Director of Discovery. Upon Selcia’s acquisition by Eurofins in 2017, she has become general manager of Eurofins Discovery and additionally taken on a global role as Business Line Leader of Integrated Drug Discovery Services at Eurofins Discovery. Vicky has a strong track record in innovative medicinal chemistry, and has delivered multiple pre-clinical candidates for customers. She is named on around 30 papers and patents and is a Fellow of the Royal Society of Chemistry.

Drug discovery: Collaborations between CROs and the Pharmaceutical Industry

The role of CROs in supporting the drug discovery industry has evolved from providing pairs of hands to carry out certain simple pre-designated tasks to provide solutions to customer’s challenges and now are evolving further to provide innovation in the form of project ideas. Collaborative partnerships on integrated drug discovery projects are now common in the drug discovery landscape. This presentation will cover the advantages of outsourcing, business models, integrated outsourcing vs using many specialist providers, trends in the outsourcing environment and strategic alliances between CROs.

Head of Discovery Operations, RNA Molecule Research (RMR)
Pharma Research and Early Discovery (pRED)
Roche Innovation Center Copenhagen (RICC)

As Head of Discovery Operations, RMR Christoph is responsible for leading the Oligonucleotides synthesis, Pharmacology, and Screening Operations teams and as a member of the RMR-LT he participates in defining and setting the strategy for RMR.

 Christoph holds a Master of Science and a Ph.D. in Organic Chemistry from the University of Southern Denmark (the lab of Prof. Jesper Wengel - one of the inventors of LNA). After his PhD, Christoph worked as a post-doctoral fellow at the Danish Technical Univerisity. In addition Christoph holds an executive MBA in Technology, Market and Organisation from Copenhagen Business School.

Christoph started his biotech career in Cureon as chemist with the task of synthesizing the LNA monomers. The company was later merged with Pantheco A/S to create Santaris Pharma A/S in 2003, where he become group leader for the chemistry team. Later the group was joined with CMC, Bioinformatics, PK and Pharmacolgy to form the Research Operation Department for which he became the director. A position he held until the acquisition by Roche in 2014.

Dr. Christoph Rosenbohm will speak about the opportunities and challenges encountered when a “mature” technology in a well-established CMO partnership needs to change. New compounds that need to be made as custom manufacturing are entering the partnership and the established compounds LNA phosphoramidites are becoming commodities with other vendors entering into the supplier landscape.

Alessandro Fazio works as R&D Outsourcing Manager (Non-Clinical) at Chiesi Farmaceutici Spa since 2017 (Parma, Italy). He is mainly responsible for managing the outsourcing activities within the Preclinical area (drug discovery, medicinal chemistry, toxicology, pharmacology and DMPK) and the CMC area for biologics (protein, enzyme and cell culture).

Alessandro holds a PhD in Systems Biology from the Technical University of Denmark and he worked as Optimization Scientist for enzyme production at Novozymes A/S and as Innovation Project Manager for Commercial Development at Chr Hansen A/S (both positions in Copenhagen, Denmark).

Effective Supplier Relationship development though the Supplier Relationship Mapping.

Supplier Relationship Mapping is a process involving a number of different tools and techniques, that can provide Pharma R&D with competitive advantages through the analysis, management and leverage of their relationships with R&D service providers. Both Pharma R&D and Outsourcing departments should develop a structured understanding of the status quo, deeply investigating the nature of current relationships that exist within and between Pharma R&D organizations and their service providers.

Supplier Relationship Mapping relies on five core concepts: (i) Balance of power; (ii) Supplier preferencing; (iii) Supplier constituency mapping; (iv) Reverse marketing; (v) Relationship management. Supplier Relationship Mapping should be run together with Portfolio Analysis, a tool to help Pharma R&D identifying appropriate strategic options and tactical actions based on two of the most critical aspects of R&D services’ market: (a) Market difficulty/risk, and (b) Relative value/profit impact.

The combination of understanding Pharma R&D position from service providers’ viewpoint and understanding service providers’ position vis à vis the marketplace, enhances Pharma R&D strategic decision-making process, thus leading to a well-chosen outsourcing approach

Alessandro Fazio works as R&D Outsourcing Manager (Non-Clinical) at Chiesi Farmaceutici Spa since 2017 (Parma, Italy). He is mainly responsible for managing the outsourcing activities within the Preclinical area (drug discovery, medicinal chemistry, toxicology, pharmacology and DMPK) and the CMC area for biologics (protein, enzyme and cell culture).

Alessandro holds a PhD in Systems Biology from the Technical University of Denmark and he worked as Optimization Scientist for enzyme production at Novozymes A/S and as Innovation Project Manager for Commercial Development at Chr Hansen A/S (both positions in Copenhagen, Denmark).

Effective Supplier Relationship development though the Supplier Relationship Mapping.

Supplier Relationship Mapping is a process involving a number of different tools and techniques, that can provide Pharma R&D with competitive advantages through the analysis, management and leverage of their relationships with R&D service providers. Both Pharma R&D and Outsourcing departments should develop a structured understanding of the status quo, deeply investigating the nature of current relationships that exist within and between Pharma R&D organizations and their service providers.

Supplier Relationship Mapping relies on five core concepts: (i) Balance of power; (ii) Supplier preferencing; (iii) Supplier constituency mapping; (iv) Reverse marketing; (v) Relationship management. Supplier Relationship Mapping should be run together with Portfolio Analysis, a tool to help Pharma R&D identifying appropriate strategic options and tactical actions based on two of the most critical aspects of R&D services’ market: (a) Market difficulty/risk, and (b) Relative value/profit impact.

The combination of understanding Pharma R&D position from service providers’ viewpoint and understanding service providers’ position vis à vis the marketplace, enhances Pharma R&D strategic decision-making process, thus leading to a well-chosen outsourcing approach

Duncan is an enthusiastic and accomplished medicinal chemist with extensive outsourcing experience, a 40-year proven track record with a Blue-Chip Pharmaceutical Company, and is the founder of Awridian Ltd.

Duncan has made significant contributions to numerous drug discovery projects, and is cited on many patents and publications including research areas such as prostaglandin agonists, histamine H2, opioids, angiotensin II and CCR3 receptor antagonists. He has been pivotal numerous lead generation projects gaining a unique insight into project and compound tractability. He has extensive outsourcing experience including projects to enhance screening collections, where he engaged with external partners to design, and synthesise appropriate compounds in a cost effective and timely manner. Duncan has recently published and presented on Open Innovation in Drug Discovery for which he is a strong advocate. He was a founder member of the DiscoverAssist™ Panel at the Stevenage Bioscience Catalyst.

Duncan formed his consultancy company (Awridian Ltd) in 2012, and is currently working with a range of international companies and UK academics.

Roelof de Wilde received his MSc degree in Molecular Biology and Biotechnology from the University of Groningen, the Netherlands. He started his professional career as Study Director at SOLVO Biotechnology, Budapest, Hungary, where his main responsibilities were conducting contract-based research in the lab on drug - membrane transporter interactions. Following this, from 2012 to 2016 he served clients in North-American territory as Study Manager, during which he was responsible for close to 200 contract research studies. During this period he also designed a series of data analysis and interpretation templates, to streamline internal data processing as well as helped implementing new techniques to study transporter interactions in SOLVO’s labs (hepatocyte uptake and B-clear® assays). In 2016 his responsibilities increased in a new role as Head of the North-American team, moving into a more business oriented position. After a short transition period as Head of the European team he was promoted to Director of Sales in the end of 2017, becoming responsible for both the European and Asian-Pacific business development. Backed up by his strong technical background and experience working with clients in the pharmaceutical industry globally, he is currently managing a team of several Study- and Account Managers.

Thomas studied chemistry in France (ENSC, Montpellier) and the UK (UMIST, Manchester) and obtained a PhD degree from the university of Nottingham, UK.

After research appointments at the School of Pharmacy in Nottingham and ETH Zürich, Thomas joined Lipideon Biotechnology AG in 2007. As Head of the Drug Discovery and Chemistry, he lead a multi-disciplinary team that discovered a candidate for pre-clinical investigation (Non-Systemic Cholesterol Absorption Inhibitor).

In 2011, Thomas co-founded SpiroChem AG, Swiss fine chemicals company and serves as CEO of the company.

Thomas has several years of experience in the management of R&D projects, including medicinal chemistry, design of innovative building blocks for drug discovery and development of new process routes.

Dr Robert Kirby, Head of CRO Services, will be substituting Andy Southan.

Andy has over 25 years’ experience in life science research, including 14 years in the CRO sector.  In 1991 he received his PhD in Pharmacology from the University of London (UK), investigating the effects of anaesthetics and high pressure on CNS potassium channels.  Following a move to industry Andy worked as a brain slice electrophysiologist supporting ion channel-based CNS programmes at Wyeth (UK), before moving to Imperial College London where he published the first patch-clamp recordings from cerebellar inhibitory nerve terminals.  At CeNeS Pharmaceuticals he performed CRO services (hERG, nAChR) and internal research on HCN and two-pore channels.  He subsequently established the electrophysiology laboratory for Ionix Pharmaceuticals, a company focused on identifying novel pain therapeutics, where he worked on Na_v, Ca_v and mechanosenstive ion channels.  Before joining Metrion, Andy spent 12 years in leadership roles at BioFocus and Charles River managing stand-alone projects, multi-year collaborations and fully integrated drug discovery programmes.

Dr. Fred Jordan is co-founder of AlpVision and has served as CEO since June 2001. He is the author of numerous scientific publications and patents. Dr. Jordan has work experience in the United States and in France. In 1999, he received his PhD from the Swiss Technology Institute (EPFL) - Signal Processing Institute (ITS) in Lausanne.

AlpVision is providing solutions based on Artificial Intelligence to improve every aspects of research in biotech. For instance, we are currently working on following topics:

- Prediction of chemical reactions yields for the synthesis of small molecules.

- Prediction of performance of medical devices

- Automatic analysis of microscope images, in particular for cell culture (confluence, counting, etc)

Tammy Ladduwahetty is a Group Leader in Medicinal Chemistry at the Charles River Early Discovery site in the UK. During her >10 years at Charles River she has led medicinal chemistry and library design teams and worked on a number of target classes including GPCRs, ion channels, kinases and nuclear hormone receptors. She has experience in a range of therapeutic areas from CNS disease to antimalarials. After obtaining her Ph.D. from the University of Pennsylvania and spending a post-doctoral year at Cambridge University, Tammy joined Merck Sharp and Dohme in the UK. During her eighteen year career there she was a key contributor to a number of clinical candidates, including the NK1 antagonist Emend which is on the market for CINV. She is the co-author of over 60 patents and papers.

Capture Compound Mass Spectrometry (CCMS) is an unbiased, proteome-wide approach for the identification of specific-binding protein targets for small molecules and peptides. The technology combines medicinal chemistry and in vitro pharmacology, coupled to high resolution proteomics mass spectrometry to isolate and identify target proteins that are responsible for an observed biological response. This technology can be used in a variety of contexts from target de-convolution and drug re-purposing to identification of off-target activities. Example case studies where CCMS technology have been used in-house are presented. The first involves target deconvolution for hits from a phenotypic assay and the second illustrates the use of CCMS to determine the hepatotoxicity causing off-target of the catechol-O-methyl transferase (COMT) inhibitor tolcapone.

Tom has spent 20 years in strategic procurement roles in various large corporations. He has been with Scientist.com since 2017, but his connection to the company goes back more than 5 years, when he was leading the AstraZeneca Global Research Procurement team. At AstraZeneca, Tom led the strategic development and successful implementation of digitalisation strategy involving the Scientist.com marketplace across the global business. His current role is to develop new customer relationships and support partners in their strategic program development by leveraging his years of industry experience. Tom holds a MSc in Global Supply Chain Management from Southampton University.

Digitalisation of business processes and drug development is a trend that will not be going away anytime soon. See how the worlds best pharma and Biotech companies have transformationally digitalised their research outsourcing processes and gain great insight into the art of the possible. Current outsourcing processes are laborious and antiquated (think Blockbuster Video). Now see how you can turn your research outsourcing into simple, fast, on-demand services....BE MORE NETFLIX

Tom has spent 20 years in strategic procurement roles in various large corporations. He has been with Scientist.com since 2017, but his connection to the company goes back more than 5 years, when he was leading the AstraZeneca Global Research Procurement team. At AstraZeneca, Tom led the strategic development and successful implementation of digitalisation strategy involving the Scientist.com marketplace across the global business. His current role is to develop new customer relationships and support partners in their strategic program development by leveraging his years of industry experience. Tom holds a MSc in Global Supply Chain Management from Southampton University.

Digitalisation of business processes and drug development is a trend that will not be going away anytime soon. See how the worlds best pharma and Biotech companies have transformationally digitalised their research outsourcing processes and gain great insight into the art of the possible. Current outsourcing processes are laborious and antiquated (think Blockbuster Video). Now see how you can turn your research outsourcing into simple, fast, on-demand services....BE MORE NETFLIX

Tom has spent 20 years in strategic procurement roles in various large corporations. He has been with Scientist.com since 2017, but his connection to the company goes back more than 5 years, when he was leading the AstraZeneca Global Research Procurement team. At AstraZeneca, Tom led the strategic development and successful implementation of digitalisation strategy involving the Scientist.com marketplace across the global business. His current role is to develop new customer relationships and support partners in their strategic program development by leveraging his years of industry experience. Tom holds a MSc in Global Supply Chain Management from Southampton University.

Digitalisation of business processes and drug development is a trend that will not be going away anytime soon. See how the worlds best pharma and Biotech companies have transformationally digitalised their research outsourcing processes and gain great insight into the art of the possible. Current outsourcing processes are laborious and antiquated (think Blockbuster Video). Now see how you can turn your research outsourcing into simple, fast, on-demand services....BE MORE NETFLIX

Inez is a pharmaceutical professional with extensive experience within the pharma and biotech industry. In-depth knowledge of the different elements of drug development and the interfaces between them. As partner and co-founder of 3D-PharmXchange she is responsible for the strategy and management of 3D-PharmXchange. In 2013 she was appointed as CEO for our client Treeway, a biotechnology company with a mission to develop therapies to cure ALS.

Her interests are in the strategic aspects and the valuation of drug and companion diagnostic development projects, as well as the potential for collaboration and synergy in this development space between big pharma and smaller biotech companies. She has a passion for driving results that truly impact critical decisions through leadership and/or participation in multidisciplinary efforts at the interface between science and business.

Prior to founding 3D-PharmXchange, she was Director Clinical Development and Chief Operating Officer of Kinesis Pharma. She also worked for several years as consultant and project manager on clinical and PK-PD projects in several therapeutic areas.

At Tibotec-Virco, she managed the clinical pharmacology program for their successfully approved HIV protease inhibitor Prezistra and follow-up compounds.  At Leiden Advanced Experts on PK and PD (LAP&P) she was responsible for modeling & simulation projects and project management.

Inez studied Medical Biology at the University of Amsterdam, The Netherlands, and obtained her PhD at the department of Pharmacology from the LACDR at Leiden University, The Netherlands. 

Inez de Greef, CEO, will speak about the discovery pipeline of Treeway. Inez will speak about the long history of GDNF and how Treeway is developing an AAV5-GDNF gene therapy for the indication ALS. In addition, she will present Project Mine, a genetic research project to identify new ALS targets and Treeway’s current target validation programme.

Garry Pairaudeauis currently Head of Hit Discovery at AstraZeneca; the group comprising HTS, Comp Chem, Virtual screening and DEL is responsible for generating high quality starting points for AstraZeneca. In addition, the group works extensively with academic centres of excellence through open innovation and strategic collaborations with groups such as MRC, CRUK, Life Arc and many others to help support academic drug discovery.

Garry also chairs the Global Chemistry Leadership team in AstraZeneca responsible for chemistry strategy and has been particularly active in building Automation and Machine learning capabilities in addition to continuing to lead AZ Discovery chemistry outsourcing.

Garry obtained his PhD in chemistry from the University of Southampton in 1991, followed by post-doctoral work at UC Irvine California.  He joined AstraZeneca in 1994 as a medicinal chemist and was part of the chemistry team that discovered Brilinta. He has experience leading projects through all phases of Drug Discovery contributing to multiple clinical candidates in the respiratory, inflammation and CV areas. He has a long standing interest in lead generation, hit identification and diversity screening.  Prior to taking up his current position in 2012 he was Director of Chemistry for the cardiovascular group at Alderley Park.

PhD from University of Barcelona and Post-doc at University of Sheffield with Prof V. Aggarwal.

Joined Almirall in 1998 as a member of the starting Combinatorial Chemistry Group. From 2000 to 2008 worked as chemistry program leader working on a variety of targets including GPCRs, enzymes, chemokines and ion channels in the Respiratory therapeutic area. Since 2009 promoted to Medicinal Chemistry Head of Section and Inhalation Team Leader of a multidisciplinary group devoted to the design of inhaled drugs. Since 2015 involved in Idea Generation Groups for developing incremental innovation and repositioning projects.

Worked in several strategic collaborative programs and in 2018 promoted to Head of Research Alliances of a group responsible for running collaborations with other Biotechs, CROs and academic groups, obtain public funding and coordinate open innovation initiatives.

Dr. Delgado joined BaseLaunch in 2018 as Manager Innovation & Sourcing. He is responsible for scouting early-stage therapeutic innovation across continental Europe and also for supporting portfolio companies in important operational activities such as: de-risking science, team building, fundraising and connecting to Pharma and Venture Capital investors.

Dr. Eberhard Krauß is Group Leader in the In Vitro Biology department at the Evotec site in Toulouse, France, overseeing a number of internal and external projects in oncology as well as various technology platforms such as ex vivo culture, single cell RNAseq, CRISPR and high-content imaging. One of his current responsibilities is leadership of several target identification and validation activities. In 2014, Eberhard co-founded and implemented VIB Discovery Sciences enabling to translate basic research outcomes into early drug discovery programmes. Previously, he has been supporting scientists and teams during various positions in industry (Tibotec/Janssen) and academia in technology selection, target identification & validation, development particularly of physiologically more relevant cell-based assays, screening, and drug discovery (oncology, infectious diseases, CNS). In 2003-2008, he was setting-up and heading the central high-content screening labs at the Max Planck Institute in Dresden, Germany. Before, he held responsible positions for 6 years in biotech industry at Cenix BioScience (Germany) and Cyclacel (Scotland, UK) dealing with RNA interference (RNAi) and drug discovery, respectively.

Dr. Eberhard Krauß is Group Leader in the In Vitro Biology department at the Evotec site in Toulouse, France, overseeing a number of internal and external projects in oncology as well as various technology platforms such as ex vivo culture, single cell RNAseq, CRISPR and high-content imaging. One of his current responsibilities is leadership of several target identification and validation activities. In 2014, Eberhard co-founded and implemented VIB Discovery Sciences enabling to translate basic research outcomes into early drug discovery programmes. Previously, he has been supporting scientists and teams during various positions in industry (Tibotec/Janssen) and academia in technology selection, target identification & validation, development particularly of physiologically more relevant cell-based assays, screening, and drug discovery (oncology, infectious diseases, CNS). In 2003-2008, he was setting-up and heading the central high-content screening labs at the Max Planck Institute in Dresden, Germany. Before, he held responsible positions for 6 years in biotech industry at Cenix BioScience (Germany) and Cyclacel (Scotland, UK) dealing with RNA interference (RNAi) and drug discovery, respectively.

Brian has had a highly successful career in drug discovery in industry with GSK and Novartis. Brian has a BSc in Pharmacy and PhD from the University of Manchester where he worked on novel antifungal agents. This was followed by Post Doctoral study at the University looking at novel opioid-like analgesics, then a two-year industrial Post Doctoral position at Schering Plough in New Jersey focussed on the total synthesis of the marine natural products Pseudopterosins.

Brian then spent 12 years at Glaxo/GlaxoWellcome/GSK working in many different disease areas (CNS, respiratory, cardiovascular, GI and antibacterials). Moving to Novartis (Horsham) in 2002 he became Head of Chemistry with the site specialising in respiratory and GI research, as well as acting as an expertise hub for automated synthesis for the Novartis chemistry organisation (Global Discovery Chemistry). He developed a keen interest in the modulation of ion channels as a target class and the design of inhaled medicines, which he is now a recognised expert in.

Brian moved to the University of Sussex (November 2014), where he is now Professor of Pharmaceutical Chemistry growing a medicinal chemistry platform underpinned by extensive automated synthesis capability. His group’s focus is the application of high throughput automated synthesis in hit and lead optimisation and the synthesis of novel archive diversity enhancement libraries. Along with Professor Kevin Booker-Milburn, he is co-founder and co-director of Photodiversity Ltd, a start-up company from the Universities of Sussex and Bristol which specialises in the use of Photochemistry to produce novel sp3 rich fragment and diversity libraries for screening against Pharmaceutical and agrochemical biological targets.

He is a Fellow of the Royal Pharmaceutical Society of Great Britain and registered pharmacist, Fellow of the Royal Society of Chemistry, chartered Chemist and chartered scientist. He is a member of the Royal Society of Chemistry’s Chemistry organic and Medicinal Chemistry Sector committee. He is associated with a number of marketed compounds and multiple late stage clinical candidates and is a champion of diversity and inclusion (D&I).

PhD from Imperial College. Joined Glaxo in 1984 and stayed until 2009 worked on a variety of targets including ion channels, GPCRs, nuclear receptors and enzymes. During the GSK era worked in the Neurology area as a department head in Medicinal Chemistry largely focussed on pain programmes.

Left GSK in 2008 and joined Almirall in Barcelona as Head of Chemistry where the focus was on respiratory projects and inhaled delivery and in 2013 returned to the UK to join the Drug Discovery Group at the University of Sussex with the responsibility of developing collaborations with both academic groups and industry and raised 12.5M in funding to support the group’s activities.

Started working with Bicycle in 2016 as a consultant while still at Sussex and joined as Director of Chemistry in October 2018

Brice is a Director Drug Discovery at Medicines for Malaria Venture (MMV). He leads drug discovery activities in the context of individual projects and pharmacology platforms. As Director Drug Discovery, Brice provides scientific advices and leadership to portfolio of drug discovery activities projects and pharmacology platforms. He works with partners from both academia and industry in order to deliver pertinent and optimal biological test cascades as well as safe and efficacious pre-clinical candidate which will be part of the next generation of anti-malarials. Brice has a particular interest in molecules and biological assays that tackle the liver stage of the parasite and more precisely the hypnozoites reservoir in order to find the new drugs that will help eradicate Malaria.

He joined MMV in November 2011, bringing with him more than 14 years of experience in drug discovery, gained primarily with the Genomic Institute of the Novartis Foundation (GNF) and Addex Pharmaceuticals S.A. He has broad experience in molecular pharmacology and drug discovery in several disease areas such as Neuroscience, Metabolic Disease and Inflammation, and has successfully led and contributed to teams at all stages of drug discovery. Brice holds a PhD in Neuroscience and Immunology from the University of Sheffield (UK) and has published a significant number of scientific papers and patent applications.

Werngard Czechtizky obtained her PhD at ETH Zürich. After a postdoctoral stay at Harvard University, she worked on GPCR lead generation in a global Chemical Biology platform at Aventis. At Sanofi, from 2005, she moved into a parallel synthesis team working in the fields of CNS and CV diseases. In 2010, she became leader of a Medicinal Chemistry section working on Diabetes programs. In 2014, she was appointed Head of Chemistry at Sanofi R&D Germany, with therapeutic focus on Diabetes, pain and inflammatory indications. Since 2017, she is Head of Medicinal Chemistry, Respiratory, Inflammation and Autoimmunity, at AstraZeneca in Sweden.

Professor Chris Frampton obtained his B.Sc in Chemistry and his Ph.D in Inorganic Chemistry from the University of Essex in 1981 and 1985 respectively. After completion of his Ph.D research he took up a postdoctoral position in the laboratory of Professors Tom Birchall and Ron Gillespie at McMaster University Hamilton, Ontario, Canada, researching into the correlation of crystal structure data with Mössbauer spectroscopic parameters of high-oxidation state main-group compounds. He subsequently took up the management position of the single-crystal X-ray facility at McMaster University. Prior to his more recent academic positions, Professor Frampton was a cofounder and Chief Scientific Advisor of Nuformix (2009), a company devoted to the exploitation of cocrystal technology to improve the pharmaceutical characteristics and generate new IP for new and existing drug products. Cofounder and Director of Pharmorphix Ltd. (July 2003-May 2014), consultancy and solid-form research services to the pharmaceutical and biotechnology sectors. He joined Pharmorphix full time in January 2005 as Chief Scientific Officer. Pharmorphix was acquired by SAFC Pharma, A Sigma-Aldrich Company Ltd. in August 2006 and more recently by Johnson Matthey PLC, October 2015.

He held the position of Director of Strategic Marketing at Bruker AXS where he was responsible for new technology in the bio-market. He joined Bruker AXS after 9 years at Roche Discovery Welwyn, a UK-based semi-autonomous research and development division of F. Hoffman La-Roche AG, with the primary responsibility for the establishment of a single crystal X-ray diffraction laboratory to support both medicinal chemistry and the pre-clinical Pharmaceutical Development Department. This included participating in research projects that led to the successful market launch of drugs such as the influenza neuraminidase inhibitor Tamiflu® (oseltamivir phosphate) and a first-generation HIV protease inhibitor Invirase® (saquinivir mesylate). He is the author and co-author of over 30+ patents and over 140 peer-reviewed research publications which have appeared in many high-impact journals. He is a member of the editorial board of for the IUCr journal Acta Crystallographica, Sect. C.

He has acted as an expert witness in a number of high profile legal cases, involving the solid form of pharmaceutical drug substances, in both the US and the UK. More recently, (November 2013- January 2018), he took a Chair in Structural Chemistry and Crystal Engineering within the Wolfson Centre for Materials Processing at Brunel University and currently holds the post of visiting Professor of Structural Chemistry within the ETC at Brunel University. In April 2015 he was named in the Global Top 100 Most Influential Medicine Makers Power List. He is currently the CEO of Rbar3 Ltd., a Solid-form and Crystallographic Consultancy service to the pharmaceutical and fine chemical industry sectors

Professor Chris Frampton obtained his B.Sc in Chemistry and his Ph.D in Inorganic Chemistry from the University of Essex in 1981 and 1985 respectively. After completion of his Ph.D research he took up a postdoctoral position in the laboratory of Professors Tom Birchall and Ron Gillespie at McMaster University Hamilton, Ontario, Canada, researching into the correlation of crystal structure data with Mössbauer spectroscopic parameters of high-oxidation state main-group compounds. He subsequently took up the management position of the single-crystal X-ray facility at McMaster University. Prior to his more recent academic positions, Professor Frampton was a cofounder and Chief Scientific Advisor of Nuformix (2009), a company devoted to the exploitation of cocrystal technology to improve the pharmaceutical characteristics and generate new IP for new and existing drug products. Cofounder and Director of Pharmorphix Ltd. (July 2003-May 2014), consultancy and solid-form research services to the pharmaceutical and biotechnology sectors. He joined Pharmorphix full time in January 2005 as Chief Scientific Officer. Pharmorphix was acquired by SAFC Pharma, A Sigma-Aldrich Company Ltd. in August 2006 and more recently by Johnson Matthey PLC, October 2015.

He held the position of Director of Strategic Marketing at Bruker AXS where he was responsible for new technology in the bio-market. He joined Bruker AXS after 9 years at Roche Discovery Welwyn, a UK-based semi-autonomous research and development division of F. Hoffman La-Roche AG, with the primary responsibility for the establishment of a single crystal X-ray diffraction laboratory to support both medicinal chemistry and the pre-clinical Pharmaceutical Development Department. This included participating in research projects that led to the successful market launch of drugs such as the influenza neuraminidase inhibitor Tamiflu® (oseltamivir phosphate) and a first-generation HIV protease inhibitor Invirase® (saquinivir mesylate). He is the author and co-author of over 30+ patents and over 140 peer-reviewed research publications which have appeared in many high-impact journals. He is a member of the editorial board of for the IUCr journal Acta Crystallographica, Sect. C.

He has acted as an expert witness in a number of high profile legal cases, involving the solid form of pharmaceutical drug substances, in both the US and the UK. More recently, (November 2013- January 2018), he took a Chair in Structural Chemistry and Crystal Engineering within the Wolfson Centre for Materials Processing at Brunel University and currently holds the post of visiting Professor of Structural Chemistry within the ETC at Brunel University. In April 2015 he was named in the Global Top 100 Most Influential Medicine Makers Power List. He is currently the CEO of Rbar3 Ltd., a Solid-form and Crystallographic Consultancy service to the pharmaceutical and fine chemical industry sectors